Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics, Nikon Ink Italian Distribution Deal for DNA-FISH Probes

NEW YORK (GenomeWeb News) – Cancer Genetics today said that it and Nikon's Italian subsidiaries have entered into a distribution agreement covering Cancer Genetics' DNA probes intended for fluorescent in situ hybridization.

The deal between Cancer Genetics Italia and Nikon Instruments SpA is also anticipated to expand into other countries in Western Europe, where more than 350,000 FISH-based diagnostic tests are performed annually, Rutherford, NJ-based Cancer Genetics said.

Nikon offers microscopes and imaging software systems that improve workflow efficiency and reduce subjectivity in cytogenetics laboratories. Its technology in combination with Cancer Genetics' DNA-FISH probes "will allow laboratories to perform simultaneous multicolor FISH testing with complex image analysis in academic and clinical settings," Cancer Genetics, which went public last month, said.

In Italy about 70,000 FISH-based tests are carried out each year, and the partnership announced today is expected "to rapidly gain market share in Italy through the offering of a complete solution, including microscopy and reagents, to cytogenetics and cancer laboratories."

Financial and other terms of the deal were not disclosed.

"This partnership allows us to complete our instrumentation and consumables line for FISH applications," said Nikon's Cristiana Ricci. "Nikon has developed, especially for the oncology/hematology field, a microspots system to investigate FISH on a microchannel, and CGI Italia's probes are very important to complete our full solution offer for our customers."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.